翔宇医疗23年报&24一季报交流240422东吴原文 2024年04月22日16:38 发言人100:04 市场环境，我们全体侠旅人还是深耕主业，不忘初心，党抓机遇，展现出了持续向上任性成长的充沛动 能和潜能，为公司上市三周年交出了一份实干奋进的答卷。并且我们始终将全体股东以及投资者的利益 这一个相信大家会对翔宇的经营策略以及投资价值有进一步的了解。下面由祥宇公司董事会办公室的董 秘助理石晓夏女士，像2023年以及24年一季报的情情况，做个简单向大家做个简单介绍,请想象中。 一手 股市调研 发言人2 01:12 好，感谢董事长，感谢各位分析师。投资者朋友大家下午好。我是祥云医疗的总秘助理石小夏。公司 于4月18号披露了2023年的年度报告，以及2024年的一季报，受到了大家的广泛很关注。下面由我把公 司的整体的经营情况给大家做个简要的介绍。 运转卖， ：股市调研 发言人2 02:07 同时公司切实履行以投资者为本的理念，为增强投资者的回报，提升投资者的获得，2023年拟实施 每10股派件5.3元的分红方案，占到公司规模净利润的比例提高到了36.36%。2024年一季度，在春节假 期淡季的因素，叠加去年高基数的 ...

2024 年 4 月 18 日 收益表现 % 1M 3M 1Y 相对 -17.37 -23.39 6.92 绝对 -18.43 -14.51 -6.90 资料来源：Wind 公司研究 2023 年经营强势复苏，股权激励彰显信心 增持（维持） 当前价：40.18 元 作者 分析师：黄素青 执业证书编号：S0930521080001 021-52523570 huangsuqing@ebscn.com 事件 1：公司发布 2023 年年报，实现营业收入、归母净利润、扣非归母净利润分别 为 7.45/2.27/2.04 亿元，同比+52%/81%/162%。经营活动现金流量净额 2.28 亿元， 同比+22%；EPS（基本）1.44 元。拟向全体股东每 10 股派发现金红利 5.30 元（含 税），股利支付率为 36.36%。业绩符合市场预期。 点评： 要点 2023 年公司经营强势复苏，盈利能力明显修复。4Q23 公司实现营业收入、归母净 利润、扣非归母净利润 2.03/0.48/0.39 亿元，同比+54%/47%/79%，扣非归母净利 润增速快于收入，与期间费用率的正常回落有关。随着疫后经济活动的恢复和康复 ...

河南翔宇医疗设备股份有限公司 审计报告及财务报表 二〇二三年度 信会师报字[2024]第 ZE10126 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ztc.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zcc.mof.gov.cn）"进行查询 ， 【 河南翔宇医疗设备股份有限公司 审计报告及财务报表 (2023年01月01日至2023年12月31日止) | 目录 | 页次 | | --- | --- | | 审计报告 | l -ર | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-118 | IBDO ? 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 审计报告 信会师报字[2024]第 ZE10126 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 169,097,488.82, representing an increase of 18.12% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 39,073,828.52, reflecting a growth of 3.34% year-on-year[6]. - The net profit after deducting non-recurring gains and losses increased by 12.07% to CNY 36,482,745.51[4]. - Basic earnings per share rose by 4.17% to CNY 0.25, while diluted earnings per share increased by 8.33% to CNY 0.26[4]. - Total revenue for Q1 2024 was CNY 143,153,527.80, a decrease of 15.4% compared to CNY 169,097,488.82 in Q1 2023[19]. - Operating profit for Q1 2024 increased to CNY 44,155,701.28, compared to CNY 42,209,940.11 in Q1 2023, reflecting a growth of 4.6%[20]. - Net profit for Q1 2024 was CNY 38,592,209.22, slightly down from CNY 38,725,982.66 in Q1 2023, indicating a decrease of 0.3%[21]. - Earnings per share for Q1 2024 were CNY 0.24, compared to CNY 0.25 in Q1 2023, showing a decline of 4%[21]. - The company reported a net profit for Q1 2024 of CNY 35,128,486.74, a decrease of 13.5% from CNY 40,608,258.68 in Q1 2023[29]. Cash Flow and Assets - The net cash flow from operating activities decreased by 52.55% to CNY 17,295,631.36, primarily due to higher cash payments related to operating activities[6]. - The company's cash and cash equivalents decreased to CNY 287,015,000.00 in Q1 2024 from CNY 27,015,000.00 in Q1 2023, indicating a substantial increase of 964.5%[18]. - In Q1 2024, the company's operating cash inflow was CNY 175,052,571.80, a decrease of 4.1% from CNY 183,353,703.59 in Q1 2023[23]. - The total cash outflow from investment activities was CNY 184,905,943.42, significantly higher than CNY 335,845,061.28 in Q1 2023, resulting in a net cash flow from investment activities of -CNY 129,823,616.21[24]. - Cash inflow from financing activities reached CNY 267,000,000.00, compared to CNY 55,000,000.00 in Q1 2023, leading to a net cash flow from financing activities of CNY 205,139,626.91[24]. - The company's total assets as of March 31, 2024, were CNY 2,717,573,056.26, an increase from CNY 2,538,747,748.54 at the end of 2023[26]. - Current assets increased to CNY 1,339,973,202.13 from CNY 1,208,395,696.07 at the end of 2023, reflecting a growth of 10.9%[26]. - The company's cash and cash equivalents at the end of Q1 2024 were CNY 744,371,900.04, down from CNY 832,260,520.32 at the end of 2023[24]. - The total liabilities increased to CNY 701,249,031.21 from CNY 504,472,730.04 at the end of 2023, indicating a rise of 38.9%[27]. - The company's equity increased slightly to CNY 2,016,324,025.05 from CNY 2,034,275,018.50 at the end of 2023[27]. Research and Development - Research and development expenses totaled CNY 29,562,422.95, accounting for 17.48% of operating revenue, an increase of 2.39 percentage points[5]. - Research and development expenses for Q1 2024 were CNY 21,608,723.98, an increase of 0.3% from CNY 29,562,422.95 in Q1 2023[20]. - Research and development expenses increased to CNY 14,826,259.70 in Q1 2024, up from CNY 11,346,901.00 in Q1 2023, reflecting a growth of 30.5%[28]. - The company completed a project on "Key Technologies for Rehabilitation of Swallowing Disorders," which won the second prize in the China Industry-University-Research Cooperation Innovation and Promotion Award[12]. Corporate Developments - The company obtained 3 new medical device registration certificates, bringing the total to 321, and added 88 new patents, totaling 1,621 patents[11]. - The company signed an agreement with Xi'an Jiaotong University to establish a rehabilitation medical device research institute[11]. - The company was awarded the "2022 Key High-tech Enterprise Award" and recognized as a leading enterprise in digital transformation by the Henan Provincial Digital Economy Industry Association[11]. - The company’s intelligent rehabilitation equipment pilot base was included in the first batch of pilot base construction lists in Anyang City[11]. - The company’s smart lower limb feedback training system and other rehabilitation devices were included in the "Directory of Rehabilitation Aids (2023 Edition)"[11]. Inventory and Receivables - The company’s total inventory as of March 31, 2024, was RMB 243,465,927.15, slightly up from RMB 241,366,072.32[16]. - The company’s long-term receivables decreased to RMB 44,756,153.84 from RMB 45,622,848.01, a decline of about 1.9%[16]. - The company reported a significant increase in prepayments, which rose to CNY 173,061,636.86 from CNY 24,608,452.94 in the previous period[26].

河南翔宇医疗设备股份有限公司 2023 年度董事会审计委员会履职情况报告 2023 年度，我们作为河南翔宇医疗设备股份有限公司（以下简称"公司"） 审计委员会委员，严格按照《上市公司治理准则》、《上海证券交易所科创板股 票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》以及《公司章程》、《董事会审计委员会工作细则》等相关法律法规及公 司制度的规定，恪尽职守、勤勉尽责，充分履行了审查、监督职能。各位委员结 合公司实际业务发展需要，积极关注生产经营状况，督促并指导公司内部审计部 门持续优化内部审计业务，同时保持与外部审计机构的充分沟通，为董事会建言 献策，督促公司各项业务合规、稳定、健康运行。现就 2023 年度工作情况向董 事会报告如下： 一、审计委员会基本情况 2021 年 12 月，公司第一届董事会任期结束，公司及时选举了第二届董事会 成员，同时第二届董事会审计委员会委员进行了选举，委员仍为叶忠明先生、郭 军玲女士、王珏女士，叶忠明先生为审计委员会召集人。 报告期内召开的董事会审计委员会会议有关情况： 三、审计委员会工作履职情况 1、监督及评估外部审计机构工作 2023 年度 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2024- 028 河南翔宇医疗设备股份有限公司关于续聘 2024年度财务审计机构及内控审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：立信会计师事务所（特殊普通合伙）。 河南翔宇医疗设备股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日 召开的第二届董事会第十七次会议和第二届监事会第十三次会议分别审议通过 了《关于续聘 2024 年度财务审计机构及内控审计机构的议案》，同意聘请立信 会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）为公司 2024 年度财务审计机构及内控审计机构，聘期一年，并提请股东大会授权公司管理层 按市场价格洽谈确定审计报酬。该议案尚需提交公司股东大会审议，具体情况公 告如下： 一、拟聘任财务审计机构及内控审计机构的基本情况 （一）机构信息 1、基本信息 立信会计师事务所由我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家 ...

海通证券股份有限公司 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为河南 翔宇医疗设备股份有限公司（以下简称"翔宇医疗"或"公司"）首次公开发行 股票并在科创板上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》等有关规定，对公司使用部分闲置募集资金暂时补充流动资金的事项 进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2021 年 1 月 26 日出具的《关于同意河南翔宇 医疗设备股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕254 号）同意，公司首次向社会公开发行人民币普通股（A 股）4,000 万股，每股发 行价格 28.82 元，募集资金总额为 115,280.00 万元，扣除发行费用后募集资金净 额为 104,965.66 万元。上述资金已全部到位，立信会计师事务所（特殊普通合伙） 对公司首次公 ...

河南翔宇医疗设备股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日召开第二届董事会第十七次会议，审议通过了《关于公司及子公司 2024 年度 向银行申请综合授信额度的议案》，现将有关事宜公告如下： 为满足公司生产经营及业务发展的资金需求，公司及子公司 2024 年度以信 用的方式拟向银行申请不超过人民币 15 亿元的综合敞口授信额度，授信期限自 本次董事会审议通过之日起 12 个月内。在此额度范围及授信期限内，授信额度 可循环使用。以上授信额度不等于公司的实际融资金额，实际融资金额应在授信 额度内，并以银行与公司实际发生的融资金额为准，具体融资金额将视公司运营 资金的实际需求来合理确定。授信业务品种包括但不限于：固定资产项目贷款、 流动资金贷款、长期借款、银行承兑汇票、商业承兑汇票、保函、信用证、并购 贷款等。 为提高工作效率，公司董事会同意授权公司董事长在上述授信额度内代表公 司签署与本次授信有关的法律文件（包括但不限于授信、借款等有关的申请书、 合同、协议、凭证等文件）。本次申请银行综合授信额度无需提交公司股东大会 审议。 特此公告。 河南翔宇医疗设备股份有限公司董事会 2024 年 4 ...

公司代码：688626 公司简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2023 年度内部控制评价报告 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 □是 √否 2. 财务报告内部控制评价结论 √有效 □无效 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日，不存在财务报告内 部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保 持了有效的财务报告内部控制。 3. 是否发现非财务报告内部控制重大缺陷 河南翔宇医疗设备股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的 ...

Financial Performance - The company plans to distribute a cash dividend of 5.30 CNY per 10 shares, totaling approximately 82.59 million CNY, which represents 36.36% of the net profit attributable to shareholders for 2023[5]. - The company's operating revenue for 2023 was CNY 744.81 million, representing a year-on-year increase of 52.46%[23]. - The net profit attributable to shareholders for 2023 was CNY 227.14 million, up 81.03% compared to the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 204.04 million, reflecting a significant increase of 162.31% year-on-year[23]. - Basic earnings per share for 2023 were CNY 1.44, an increase of 82.28% from the previous year[24]. - The company's total assets at the end of 2023 were CNY 2.59 billion, a 9.46% increase from the end of 2022[23]. - The company's net assets attributable to shareholders increased by 8.47% year-on-year, reaching CNY 2.09 billion at the end of 2023[23]. - The company reported a net cash flow from operating activities of CNY 227.91 million, up 22.07% from the previous year[23]. - The company's total revenue for the year reached approximately CNY 736.61 million, representing a year-on-year increase of 52.23%[161]. - The gross profit margin for the overall business was 69.28%, reflecting an increase of 3.11 percentage points from the previous year[161]. Research and Development - The company is investing heavily in R&D, allocating 200 million RMB for the development of innovative rehabilitation technologies[17]. - Research and development expenses accounted for 14.33% of operating revenue, a decrease of 4.59 percentage points compared to the previous year[24]. - The company added 325 new patents during the reporting period, bringing the total to 1,549 patents, including 32 invention patents[36]. - The company has developed a comprehensive product structure with over 600 proprietary products across 20 major series in the rehabilitation medical device sector[50]. - The company has established a national-level industrial design center and was recognized as a "National Enterprise Technology Center," showcasing its R&D capabilities[34]. - The company has been recognized as a leading research and development enterprise in the rehabilitation medical device industry in China[50]. - The company has obtained 318 medical device registration certificates and 1,500 patents, with 61 authorized invention patents[75]. - The company has participated in 11 national key research and development projects, including projects focused on intelligent care for disabled elderly individuals[76]. - The company has developed over 30 specialized rehabilitation solutions, including pain rehabilitation and orthopedic rehabilitation, addressing various clinical treatment needs[143]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[17]. - Xiangyu Medical plans to enter new markets in Southeast Asia, targeting a market share increase of 5% within the next two years[17]. - The company is committed to enhancing its governance structure and internal control systems to ensure compliance and protect the rights of investors[45]. - The company aims to create greater value for shareholders and society by continuously improving product quality and fostering a spirit of craftsmanship[46]. - The company is focusing on expanding its market presence through innovative product offerings and advanced rehabilitation solutions[51]. - The company is actively involved in the development of assistive robotic products for rehabilitation, addressing needs in neurological recovery and elderly care[64]. - The company aims to deepen its domestic market layout while actively expanding into international markets, focusing on differentiated and systematic rehabilitation solutions[187]. - The company is committed to building a new ecosystem in the rehabilitation and health industry through both organic growth and external acquisitions, enhancing its product range and market share[188]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any situations where more than half of the board members cannot guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The board of directors and supervisory board members have all attended the board meeting, ensuring proper governance[5]. - The company has established a timely reporting mechanism for significant matters to improve information disclosure and internal control systems[46]. - The company has implemented a 2023 restricted stock incentive plan to enhance team cohesion and align the interests of shareholders, the company, and core team members[47]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[17]. - The company focuses on providing integrated clinical rehabilitation solutions and professional technical support services to various institutions, including hospitals and rehabilitation centers[50]. - The company has over 700 marketing personnel and collaborates with clinical experts and academic institutions to identify product demand, ensuring high-quality product development that meets clinical needs[55]. - The company has implemented proactive after-sales services across all 31 provincial-level administrative regions, enhancing customer engagement and identifying new equipment needs[146]. Technological Innovation - The company is focusing on technological advancements such as robotics and telemedicine to enhance rehabilitation treatment effectiveness and efficiency[182]. - The company is leveraging cutting-edge technologies such as brain-computer interface technology and AI rehabilitation devices to accelerate the transformation of scientific achievements into productive forces[194]. - The company is developing integrated rehabilitation medical solutions by utilizing intelligent technology and human factors engineering, aiming to create over 30 clinical specialty solutions for hospitals[195]. - The company is enhancing its capabilities in rehabilitation services, particularly in the areas of prosthetics and orthopedic rehabilitation[124]. Industry Trends and Outlook - The rehabilitation medical device industry is experiencing rapid growth, supported by government policies aimed at enhancing rehabilitation services and improving public health outcomes[61]. - The demand for rehabilitation services is expected to rise significantly due to the aging population and increasing chronic disease prevalence in China[72]. - The rehabilitation medical service market in China is expected to reach CNY 268.6 billion by 2025, with a CAGR of approximately 38.5% from 2021 to 2025, indicating significant growth potential[183]. - The company is positioned to benefit from the "14th Five-Year" plan, which emphasizes the development of rehabilitation medical equipment and services[63].